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1. INTRODUCTION 
 
1.1 CAVEOLAE AND CAVEOLINS 
 
1.1.1 Caveolae 
Caveolae are vesicular invaginations of the plasma membrane of 50-
100 nm in size, found in a number of different cell types, identified for 
the first time in 1953 (Volontè D et al, 2002). They are present 
primarily in terminally differentiated mesenchymal cells including 
adipocytes, endothelial cells and fibroblasts (Smart EJ et al,1999). 
Caveolae represent a subgroup of  lipid rafts that are defined as “small 
heterogeneous membrane domains enriched in cholesterol and 
sphingolipids” (Pike L, 2006). The presence of the structural protein 
caveolin-1 drives the formation of plasma membrane invagination and 
makes caveolae unique among lipid rafts (Razani B et al, 2000). 
 
 
                                               Goetz JG et al, Cancer Metastasis Rev, 2008 
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Caveolae have been implicated in several cellular functions, including 
signal transduction: a variety of signaling molecules are preferentially 
localized in lipid rafts and caveolar membranes and interact with 
caveolin-1scaffolding domain. Cellular metabolism, vesicle 
trafficking (transcytosis, endocytosis, and potocytosis) and cholesterol 
homeostasis are also involved: caveolin-1 binds cholesterol and long-
chain unsaturated fatty acids and has been implicated in the import 
and export of cellular cholesterol by caveolae (Razani B et al, 2000; 
Williams TM and Lisanti MP, 2004; Parton RG and Simons K, 2007).  
 
 
1.1.2 Caveolins 
Three caveolin genes have been identified in mammalian cells: CAV-
1, CAV-2 and CAV-3. 
CAV-1 is composed by three exons highly conserved in their 
sequences across species. Two isoforms have been identified, the 
predominant 178-residue Cav-1α, and the 147-residue Cav-1β derived 
from an internal translation initiation site (Met
32
) (Scherer PE et al, 
1995). 
CAV-2 is composed by three exons that encode a 162-residue protein 
with a sequence highly homologous to that of Cav-1. Cav-2 α is the 
full-length protein; two additional truncated isoforms have been 
identified (Scherer PE et al, 1996). 
CAV-3 is composed by  two exons that encode a single 151-residue 
mature protein (Tang Z et al, 1996). 
CAV-1 and CAV-2 genes map to 7q31.1 near the D7S522 genetic 
marker, a known fragile site FRA7G. CAV-3 maps to 3p25. 
Caveolin-1 has been the first member of the family to be identified as 
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a structural component of caveolae and of transport Golgi-derived 
vesicles. It is ubiquitously expressed, with the highest levels in 
adipocytes, endothelial cells, fibroblasts, smooth muscle cells and a 
variety of epithelial cells (Gumbleton AG et al, 2000; Williams TM 
and Lisanti M, 2004).  
Caveolin-2 is closely co-expressed with caveolin-1 but the majority of 
caveolae require only cav-1 expression for their formation (Tagawa A 
et al, 2005; Kirkham M et al, 2008). 
Caveolin-3 is primarily located  in muscle tissues but is also expressed 
in glial cells where it plays an essential role in caveolae biogenesis 
(Galbiati F et al, 2001; Capozza F et al, 2005). 
 
 
 
                                                           
                                                                           
  
 
 
 
4 
 
1.1.3 Caveolin-1 
Cav-1 is an integral membrane protein of 22-24 KDa. It has a 
membrane spanning hairpin loop structure with  both C- and N-
terminal regions facing the cytosol. N-terminal region (N-MAD: 
NH2-terminal membrane attachment domain, amino-acids 82-101) 
can be phosphorylated by Src on its tyrosine 14 residue (Li S et al, 
1996). This modification is associated with its translocation to the 
close proximity of focal adhesions and has been linked to various 
cellular phenomena including signal transduction, endocytosis, cell 
migration and focal adhesion dynamics (Lee H  et al, 2000; Kimura A 
et al, 2002; Maggi D et al, 2002). 
C-terminal region (C-MAD: COOH-terminal attachment domain, 
amino-acids 135-150) can be palmitoylated on Cys 133, Cys 143 and 
Cys 156 and this modification is necessary for Cav-1 oligomerization 
(Dietzen DJ et al, 1995; Monier S et al, 1996). 
 
                
                                    Goetz JG et al, Cancer Metastasis Rev, 2008 
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Cav-1 can also undergo serine phosphorylation at Ser80, by which it is 
converted to a soluble secreted protein (Schegel A et al, 2001). 
Other important domains include an oligomerization domain (amino-
acids 61-101) and the scaffolding domain (CSD, amino-acids 82-101) 
(Schegel A and Lisanti MP, 2000). The last one is necessary for Cav-1 
to bind to several signalling molecules including Src family tyrosine 
kinases, growth factors receptors, endothelial nitric oxide synthase, G 
proteins and G-protein-coupled receptors (Liu P et al, 2002; Razing B 
et al, 2002) and to regulate multiple cancer-associated processes such 
as cellular transformation, tumour growth, cell migration and 
metastasis, cell death and survival, multidrug resistance and 
angiogenesis (Patel HH et al, 2008). 
 
                       
                                      Goetz JG et al, Cancer Metastasis Rev, 2008 
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1.1.4 Caveolin-1 in human tumours 
The role of Cav-1 in cancer initiation and progression is 
multidimensional. Cav-1 is highly expressed in terminally 
differentiated or quiescent cells, suggesting a possible role for it as a 
negative regulator of cell proliferation. In support of this prediction, 
several authors have demonstrated a role for Cav-1 in modulating cell 
cycle progression in mammalian cells (Glaciate F et al, 2001; Lee SW 
et al, 1998; Scheel J et al, 1999). Galbiati and colleagues (2001) have 
shown that Cav-1 expression levels are negatively regulated by 
growth factor stimuli and that recombinant over-expression of Cav-1 
can inhibit cellular proliferation, by mediating cell cycle arrest in 
G0/G1. In addition, Cav-1(–/–) null mice embryonic fibroblasts 
(MEFs) show increased proliferation rates, concomitant with 
increased S-phase fractions and decreased G0/G1 fractions, as well as 
altered expression of several cell cycle-related proteins (Razani B et 
al, 2001; Williams TM et al, 2004). Interestingly, Cav-1 has been 
shown to interact with PI3-kinase and Cav-1 over-expression 
sensitizes fibroblasts to ceramide-induced death, by a PI3-kinase-
dependent mechanism (Zundel W and Giaccia A, 1998). Furthermore, 
Cav-1 expression sensitizes both NIH-3T3 fibroblasts and T24 bladder 
carcinoma cells to cell death initiated by staurosporine, a chemical 
inducer of apoptosis (Liu J et al, 2001).  
In contrast, disruption of caveolae by cholesterol-sequestering agents 
has been shown to block IL-6 and IGF-1-induced activation of the 
PI3-kinase/Akt signaling pathway (Podar K et al, 2003). Therefore, 
caveolae and Cav-1 are required to mediate proper survival signals by 
the PI3-K/Akt pathway. Moreover, Cav-1 over-expression in Rat1A 
cells and human LNCaP prostate cancer cells or Cav-1 up-regulation 
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in androgen-insensitive LNCaP clones render these cells more 
resistant to apoptosis (Timme TM et al, 2000; Tso CL et al, 2000). In 
addition, the consequence of antisense mediated down-regulation of 
Cav-1 is a higher sensitivity of  cells to apoptosis (Li L et al, 2001; Li 
L et al, 2003). Finally, Li and colleagues (2003) have demonstrated 
that Cav-1 over-expression mediates cell survival by sustaining Akt 
activation. 
The cell type-specificity of Cav-1 effects may explain the pro-
apoptotic or anti-apoptotic functions of this protein. 
An inverse relation between Cav-1 expression and malignant 
transformation has been clearly established. During the initial 
characterization of Cav-1, it has been shown that Cav-1 levels are 
reduced in transformed NIH-3T3 cells and that the level of residual 
Cav-1 is inversely related to soft agar growth (Koleske AJ et al, 1995). 
Interestingly, reduction of Cav-1 expression by an antisense approach 
is sufficient to induce a transformed phenotype into NIH-3T3 cells, 
allowing these cells to grow in soft agar and to form tumours in 
athymic (nude) mice (Galbiati F et al, 1998). The utilization of Cav-
1(–/–) null mice served for definitive genetic evidence to support the 
idea that Cav-1 normally works as a "transformation suppressor" gene. 
Capozza et al (2003) have shown that the skin of Cav-1(–/–) mice is 
more susceptible to chemical carcinogenic treatment, resulting in the 
formation of epidermally derived tumours. In addition, genetic 
ablation of Cav-1 in MEFs render these cells more susceptible to 
transformation and in vivo tumorigenesis mediated by transforming 
oncogenes (Wiliams TM et al, 2004). Taken together, these results 
indicate that Cav-1 normally has a role to negatively regulate the 
growth and transformation of mammary epithelial cells, as well as to 
suppress the development of  advanced  mammary tumours and 
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metastasis.  
CAV-1 gene is located in chromosome 7 (7q31.1), close to a fragile 
site (FRA7G) frequently deleted in a variety of human cancers, 
including carcinomas of the breast, colon, kidney, prostate, ovary, 
head and neck (Engleman JA et al, 1998). These findings have led to 
suggest that CAV-1 may represent a tumour suppressor in this fragile 
genomic region. It is a fact that Cav-1 protein levels are low in many 
primary human cancers, ovarian, lung, and mammary carcinomas, as 
well as mesenchymal sarcomas.  Importantly, sequence analysis of 
CAV-1 in human tumours has revealed sporadic mutations. In a 
cohort of patients with primary breast cancer, Hayashi and colleagues 
(2001) have detected a sporadic P132L mutation in up to 16% of the 
cases examined. Furthermore, this mutation induces cellular 
transformation, acts in a dominant negative manner by causing the 
mislocalization and intracellular retention of wild-type Cav-1, and 
causes ERK-1/2 hyperactivation (Hayashi K et al, 2001; Lee H et al, 
2002).  
On the other hand, many cancer cell lines exhibit high expression of 
Cav-1: it is consistently up-regulated in bladder, esophagus, papillary 
thyroid and prostate carcinomas, with few exceptions (Pflug BR et al, 
1999). In addition, the levels of Cav-1 are elevated in highly 
metastatic prostate cancer cells (Yang G et al, 2000) and in multidrug 
resistant cancer cells (Cohen AW et al, 2004). 
These evidences may suggest that Cav-1 expression is correlated with 
tumour stage and grade in several types of cancer and that Cav-1 may 
act as a pro-survival  and tumour-promoting protein in advanced 
cancer. 
The positive correlation between tumour progression and metastasis 
and Cav-1 expression has been first demonstrated in prostate cancer. 
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Immunohistochemical analysis has indicated that the proportion of 
Cav-1 positive samples increases from 29% in T3N1 primary cancer 
to 56% in lymph node metastasis, whereas in normal and hyperplastic 
epithelia the percentage is 8% and 18% respectively (Yang G et al, 
1998). In addition, Cav-1 is highly expressed in primary and 
metastatic human prostate cancer after androgen ablation therapy, 
while antisense-mediated down-regulation of Cav-1 in prostate cancer 
cells in vitro reduces their metastatic phenotype (Li L et al, 2001; 
Tahir SA et al, 2001). In other reports (Ho CC et al, 2002; Joo HJ et 
al, 2204; Kato K et al, 2002; Nestl A et al, 2001), Cav-1 over-
expression has been correlated with metastasis in esophageal 
squamous cell carcinoma, clear cell renal cell carcinoma, mammary 
adenocarcinoma and metastatic cell lines derived from lung 
adenocarcinoma. These results have implications for those human 
cancers where Cav-1 is consistently down-regulated and suggest that 
the up-regulation of Cav-1 may represent an acquired feature that 
contributes to a metastatic phenotype. This concept of a "biphasic" 
expression pattern for Cav-1 has been elegantly demonstrated in colon 
carcinoma cells after selection for metastatic variants (Bender FC et 
al, 2000). This notion of two opposite roles for a protein, depending 
on the stage of tumour progression, is not unique. In early stages of 
transformation and carcinogenesis, transforming growth factor- (TGF) 
demonstrates tumour suppressive activity, by inducing cell cycle 
arrest and apoptosis, thereby inhibiting primary tumour growth 
(Benson JR et al, 2004; Roberts AB and Wakefield LM, 2003). 
However, at later stages of tumour progression, increased secretion of 
TGF- by tumour and stromal cells promotes tumour invasion, 
angiogenesis, and metastasis, as well as immunosuppression of host 
surveillance mechanisms. Therefore, the role of TGF- in 
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tumorigenesis can be either suppressive or promoting, depending on 
the tumour developmental stage. Siegel et al (2003) have definitively 
demonstrated these contrasting roles for TGF- in breast cancer by 
interbreeding transgenic mice expressing either constitutively 
activated or dominant negative forms of TGF- to MMTV-Neu/ErbB2 
transgenic mice.  
Sloan EK et al (2004), in an orthotopic model of spontaneous breast 
cancer metastasis, have shown that Cav-1 is expressed in low and non-
metastatic primary breast cancer, but at much lower levels in highly 
metastatic 4T1.2 and 4T1.13. Exogenous expression of  Cav-1 at 
moderate levels in 4T1.2 cells is sufficient to suppress primary tumour 
growth after inoculation of cells into the mammary gland. In addition, 
expression of high levels of Cav-1 also inhibits subsequent metastasis 
to distant organs. Cells expressing high levels of Cav-1 show reduced 
capacity to invade Matrigel, diminished response to laminin-1 
stimulation and decreased metastatic capacity to lung and bone. This 
study provides the functional evidence that Cav-1 negatively regulates 
tumour growth and spontaneous metastasis of breast cancer. 
Three distinct mechanisms that can serve to functionally inactivate the 
tumour suppressor function of Cav-1 have been described: tyrosine 
phosphorylation, serine phosphorylation and a dominant-negative 
point mutation, P132L. These findings may explain why Cav-1 has 
been suggested to work both as a tumour suppressor and as an 
oncogene, depending on the tumour type and/or tumour stage.  
Tyrosine Phosphorylation: The dually contrasting roles for Cav-1 in 
tumour progression may be partly explained by the observation that it 
possesses several peptide domains with opposing roles. A molecular 
dissection of the Cav-1 protein has revealed distinct regions that may 
counteract the effects of the growth-inhibitory CSD. First, Tyr14 at 
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the extreme NH2 terminus is important for the binding and recruitment 
of a c-Src/Grb7 signaling complex (Lee H et al, 2001). This residue is 
constitutively phosphorylated in v-Src- and v-Abl-transformed cells, 
transiently phosphorylated during growth factor stimulation in other 
cells, and localizes to focal adhesions, which are the predominant sites 
of tyrosine kinase signalling. Functionally, tyrosine 14-phosphorylated 
Cav-1 binds Grb7 and enhances both anchorage-independent growth 
and EGF-stimulated cell migration (Lee H et al, 2001). Thus tyrosine 
phosphorylated Cav-1 may have a role as a growth factor receptor that 
recruits SH2 domain-containing proteins to the plasma membrane. 
Cav-2 also undergoes phosphorylation (at Tyr19 and Tyr27) and 
similarly recruits SH2 domain-containing proteins, such as c-Src, Nck, 
and Ras-GAP (Lee H et al, 2002).  
Serine Phosphorylation: A second region of Cav-1 also appears to 
have growth-stimulatory properties. Serine phosphorylation of Cav-1 
changes its topology, thereby converting Cav-1 from an integral 
membrane protein to a secreted protein product. Normally, the 
majority of Cav-1 is associated with the plasma membrane. However, 
Cav-1 also appears to be secreted, especially in exocrine cell types, 
where it is packaged into secretory vesicles (Liu P et al, 2002; 
Schlegel A et al, 2001). Phosphorylation of Cav-1 at Ser80 directly 
regulates its conversion to a secreted protein. As an example, mutation 
of Ser80 to glutamate (S80E, which mimics chronic phosphorylation) 
results in preferential targeting of Cav-1 to the ER membrane and 
directs its subsequent packaging for secretion (Schlegel A et al, 2001). 
Furthermore, phosphorylation at Ser80 is necessary for a proper 
secretion because its mutation to alanine (S80A; which abrogates 
phosphorylation) results in no detectable secretion of Cav-1 (Schlegel 
A et al, 2001), concomitant with its intracellular accumulation. 
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Mechanistically, in terms of cellular transformation, shunting Cav-1 
for secretion to the extracellular environment would subvert its normal 
intracellular tumour suppressive functions. Essentially, these changes 
in Cav-1 membrane topology have the same consequences as a loss of 
Cav-1 expression.  
In addition, the secretion of Cav-1 results in a protein product that 
possesses autocrine or paracrine tumour-promoting functions. Tahir 
and colleagues (Tahir SA et al, 2001) have demonstrated that Cav-1 is 
secreted in androgen-insensitive human prostate cancer cells and that 
secreted Cav-1 acts in an autocrine/paracrine fashion, directly 
stimulating prostate tumour cell growth and survival.  
Dominant-Negative Point Mutations: The previously mentioned 
identification of Cav-1 (P132L) mutations in up to 16% of human 
breast cancers provides a third distinct mechanism to inactivate the 
tumour suppressor function of Cav-1. This mutation drives cellular 
transformation in NIH 3T3 cells. Briefly, NIH 3T3 cells expressing 
Cav-1 (P132L) show augmented growth in soft agar, as well as 
increased invasiveness, and increased chemotaxis (Hayashi K et al, 
2001).  
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  1.2 LUNG CANCER 
1.2.1 Epidemiology 
Lung cancer was a rare disease in the 19
th
 century, representing only 
1% of all tumours; at the end of the 20
th
 century, lung cancer 
incidence began to increase and now this tumour is the leading cause 
of cancer death in most industrialized countries, both in men and 
women (Jemal A et al, 2009). 
The main environmental risk factor is exposure to cigarette smoking, 
associated with more than 90% of cases of lung cancer, with active 
smoking causing the majority of these cases but with passive smoking 
also heavily contributing to the lung cancer burden (Parkin DM et al, 
2005; Jemal A et al, 2009).  
In 2002, it has been estimated that 1,35 million people throughout the 
world have been diagnosed with lung cancer and that 1,18 million per 
year died of it. In more developed countries, incidence and mortality 
rates are generally declining among males and are starting to plateau 
for females, thus reflecting previous trends in smoking prevalence. In 
contrast, there are some populations in emerging and less developed 
countries where increasing lung cancer rates are predicted to continue, 
due to endemic use of tobacco (Youlden DR et al, 2008).  
Some studies (Zang EA and Wynder EL, 1996; Wynder EL,1998; 
Baldini EH and Strauss GM, 1997; Shiver SP et al, 2000) have 
suggested that women are more susceptible than men to the 
carcinogenic effects of cigarette smoking, taking into account baseline 
exposure, body weight, height and body mass index. In a case-control 
study, Kruezer M et al (2000) haven’t found  increased odds ratio for 
female smokers compared to male smokers: there may be differences 
in baseline exposure that may alter the interpretation of these results.  
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However, a large disproportion of female-to-male cases in the never-
smoking group has been observed: a 10% of lung cancers occur in 
never-smokers and the majority of these occur in women (Egleston 
BL et al, 2009); in addition, a large proportion of these women 
presents a lung adenocarcinoma, which is a secretory tumour 
(Scagliotti GV et al, 2009). Estrogens may play a causative role in this 
phenomenon of secretory types of differentiation, known to be more 
prominent in female lung cancer (Marquez-Garbon  DC et al, 2007; 
Lim RH and Kobzik L, 2008). However, the role of oestrogen in lung 
cancer is unclear: studies indicated a positive correlation between 
post-menopausal oestrogen replacement therapy, smoking and lung 
adenocarcinoma, suggesting a role for oestrogen in lung cancer risk 
(Taioli E and Wynder EL, 1994); on the other hand, the higher 
survival rates in women than in men with NSCLC in a study of Moore 
KA et al (2003) may indicate a protective effect of oestrogen. 
Current treatment options include surgical resection, chemotherapy 
and radiotherapy alone or in combination.  Although advances in 
therapy have provided some improvement in overall survival, 
outcomes remain poor, with a five years survival for less than 15% of 
patients with lung carcinomas (Jemal A et al, 2006). Several genetic 
alterations have been recently identified in lung cancer, yet the 
investigation of new molecular markers and candidate genes that 
might be helpful for therapy remains one of the central focuses in 
cancer research. 
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1.2.2 Histological classification 
The World Health Organization (WHO) has divided lung cancers in 
four principal histological types: adenocarcinomas (30-40%), 
squamous cell carcinomas (25-40%), small cell carcinomas (20-25%) 
and large cell carcinomas (5%). However, there is a different 
classification based on biological features and manner, which divides 
lung cancers into two major  histological types: small cell lung 
cancers (SCLC) and non-small cell lung cancers (NSCLC). 
 
1.2.3 Caveolin-1 in lung cancer 
In normal adult lung, Cav-1 is expressed in alveolar type I epithelial 
cells, endothelial cells and fibroblasts. Levels of this protein are 
dynamics in tumorigenesis and these changes in the Cav-1 expression 
may affect tumour progression by influencing cell signalling. Little is 
known about the regulation of Cav-1 transcription in lung 
tumorigenesis, if it depends on cellular context and which 
environmental factors may influence its expression. 
However, a positive correlation between Cav-1 expression and tumour 
stage/grade has been reported in human lung cancers: in lung 
adenocarcinomas, nearly all metastatic lymph nodes present increased 
Cav-1 expression in tumour cells by immunochemistry (Ho CC et al, 
2002; Yoo SH et al, 2003; Kato T et al, 2004); on the other hand, in 
most primary lung tumours, Cav-1 expression is exceedingly low 
(Wikman H et al, 2002; Powell CA et al, 2003; Ho CC et al, 2002; 
Kato T et al, 2004). In addition, induced CAV-1 gene expression in a 
low-invasive lung adenocarcinoma cell line increases cell migration 
and invasiveness (Ho CC et al, 2002); instead, shRNA induced 
reduction of Cav-1 protein levels inhibits cell growth and reduces 
matrix invasion and cell migration in H129 NSCLC cells (Shatz M et 
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al, 2010). 
Previous studies reported that Cav-1 is expressed in 21-36% of 
resected primary NSCLCs and that Cav-1 expression is associated 
with poor prognosis in primary squamous cell lung cancer (Racine C 
et al, , 1999; Razani B et al, 2000; Heighway J et al, 2002; Wikman H 
et al, 2002). Moreover, Sunaga N et al (2004) suggested different roles 
for Cav-1 between SCLC and NSCLC: it can act as a tumour 
suppressor in SCLCs, whereas in NSCLC it appears to be necessary 
for tumour growth.  
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1.3 OSTEOSARCOMA 
1.3.1 Epidemiology 
Osteosarcoma is a high-grade malignant tumour composed of 
mesenchymal cells producing osteoid and immature bone with a peak 
incidence in the second decade of life (Campanacci M, 1999). In Italy, 
primary bone tumour incidence rate is approximately 0,8-1 case per 
100.000; around 500 new cases per year have been estimated and 20-
25% of these are osteosarcomas. 
Although current treatment modalities, which include surgery and 
neoadjuvant multidrug chemotherapy, significantly improved the 5-
year disease-free survival from 10% to 60%-70% (Bracci G et al, 
2005), no significant drugs or treatment approaches have been 
developed in the last 10 years, and the percentages of curative therapy 
remain unacceptably low for high-risk patients. 
The causes of osteosarcoma onset are still unknown. The correlation 
between early age and tumour appearance in the majority of patients, 
suggests that the increased osteoblastic activity, which is typical 
during high bone remodelling, may be a predisposing factor to the 
osteosarcoma onset. 
Exposure to radiation is a known causal factor: approximately 4% of 
osteosarcomas is due to previous radiotherapy for different tumours.  
A relevant involvement of genetic alterations in oncosuppressor genes 
has been demonstrated: complete or partial deletions of Rb gene have 
been found in approximately 60% of osteosarcomas. The loss of Rb 
gene, localized in the 13q14 region, is responsible of retinoblastoma 
onset, a malignant eye tumour of childhood. It may represent an 
unilateral (mostly sporadic) or bilateral (hereditary) disease. It has 
been demonstrated that patients with hereditary retinoblastoma have a 
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500-fold higher risk to develop osteosarcoma in the second decade of 
life than the healthy population. Moreover, mutations or deletions of 
p53 gene have been found in 30% to 50% of the patients with 
osteosarcoma. Mutations of p53 gene are also associated to Li-
Fraumeni syndrome which is characterized by a high incidence of 
some tumours such as osteosarcoma. 
 
1.3.2 Histological classification 
In the majority of cases, primary bone tumours are sarcomas, divided 
into osteosarcomas or chondrosarcomas on the basis of their origin 
cell type. Osteosarcomas derive from bone tissue and chondrosarcoma 
from bone cartilage. Ewing’s sarcoma is a highly aggressive and 
undifferentiated tumour that predominantly affects bones of children 
and young adults. Metastatic bone tumours are highly frequent, in 
particular those originating from breast, lung and prostate cancers. 
Osteosarcomas may represent either low-grade or high-grade 
malignancies but the most frequent form is the high-grade central 
osteosarcoma. 
 
1.3.3 Caveolin-1 and osteosarcoma 
Cav-1 is highly expressed in normal osteoblasts (Solomon KR et al, 
2000) and some experimental studies have indicated that Cav-1 can 
act as an osteoblast regulator through the modulation of endothelial 
nitric oxide synthase  enzyme activity (Lofthouse RA et al, 2001). 
This enzyme leads to the production of nitric oxide, an important 
mediator in the regulation of osteoblastic cell functions localized in 
caveolae where it binds to Cav-1 scaffolding domain. By binding to 
this enzyme, Cav-1 can modulate the production of nitric oxide and 
consequently  osteoblast activity (Lofthouse RA et al, 2001). 
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Cav-1 also impacts on osteoblasts differentiation: Rubin J et al (2007) 
have indicated that Cav-1 helps maintaining a less differentiated state 
of osteoblast progenitor cells, while its absence causes bone to 
undergo  maturation  more rapidly. Moreover, Cav-1 is involved in the 
regulation of osteoblast-mediated calcification of extracellular matrix 
inhibiting its mineralization as well as with the inhibition of 
osteoblasts differentiation.  
In addition to its involvement in bone production, Cav-1 also appears 
implicated in calcium homeostasis regulation and influences bone 
resorption (Jung SY et al, 2005). 
Compared to osteoblasts, fewer results have been reported in 
connection with the presence and functional activity of caveolins in 
osteoclasts. An extremely low expression of Cav-1 and Cav-2 in 
human osteoclasts has been observed (Luegmayr E et al, 2004); 
however, the same authors have provided evidence of its possible 
involvement in osteoclastogenesis, through its influence in cholesterol 
transport. In fact, osteoclast formation and survival are highly 
dependent on exogenous sources of cholesterol. 
In conclusion, on the basis of these evidences, although Cav-1 is 
undoubtedly involved in bone development and maturation, its role in 
these processes is still undefined and scarcely known. On one side, it 
acts as an inhibitor of osteoblastic differentiation and of bone 
maturation and mineralization. On the other, by interacting with 
calcium-sensing receptors, it can enhance bone formation and reduce 
osteclast-mediated bone resorption. The evidence emerging from the 
first study by Wiecken K et al (2001) that Cav-1 is generally down-
regulated in malignancies compared to normal cells, have suggested 
its role as an oncosuppressor in sarcomas (Wiechen K et al, 2001; 
Williams TM et al, 2004; Sloan EK et al, 2004). A better overall 
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survival rate has been observed for osteosarcoma expressing a level of 
Cav1 similar to osteoblasts (Wiechen C et al, 2001; Cantiani L et al, 
2007). Modulation of its expression in osteosarcoma cell lines greatly 
modifies the pattern of anchorage-indipendent growth, migration, 
invasion, adhesion to extracellular matrix components and, more 
importantly, their metastatic capacity. Furthermore, osteosarcoma 
cells over-expressing Cav-1 also exhibit reduced in vitro malignancy 
and decreased in vivo metastatic capacity (Zucchini C et al, 2004; 
Manara MC et al, 2006). This oncosuppressor role of Cav-1 may 
proceed through the modulation of c-Src family tyrosine kinases: in 
fact, Cav-1 is known to bind and sequester Src family kinases in an 
inactive configuration (Li S et al, 1996; Wei Y et al, 1999). Cav-1-
deprived osteosarcoma cells exhibit a marked increase in c-Src family 
tyrosine kinase activity, which significantly contributes to their 
migration and anchorage-indipendent growth (Solomon KR et al, 
2000). In contrast with these evidences, Cav-1 has been found to be 
necessary for tumorigenesis of Ewing’s sarcoma (Tirado OM et al, 
2006). These apparently contradictory findings may reflect the 
different origin and genetic features of osteosarcoma and other 
mesenchymal tumours compared with Ewing’s sarcoma and support 
the need to consider CAV-1 gene studies in its appropriate cellular 
context. Moreover, Cav-1 expression levels can be reduced, 
unchanged or up-regulated depending on the osteosarcoma cell lines 
in vitro. Thus, Cav-1 has been certainly proved to play relevant roles 
in differentiation and functions of bone and in musculoskeletal tumour 
development, however its involvement is cell context-dependent: it 
might play an oncosuppressor or a tumour promoter role by releasing 
the full oncogenic or antioncogenic properties of the proteins 
sequestered in caveolae in each tumour cell type. 
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2. MATERIALS 
Dulbecco’s Modified Eagle’s Medium (DMEM) (SIGMA-ALDRICH) 
Ham’s F12 (GIBCO-INVITROGEN) 
Foetal bovine serum (FBS) (GIBCO-INVITROGEN) 
Penicillin/streptomycin (SIGMA-ALDRICH) 
L-glutamine (SIGMA-ALDRICH) 
Mycoplasma plusTM PCR Primer Set (STRATAGENE) 
Trypsin-EDTA solution (SIGMA-ALDRICH) 
Trypan Blue (SIGMA-ALDRICH) 
Leupeptin (SIGMA-ALDRICH) 
Aprotinin (SIGMA-ALDRICH) 
4- (2-aminoethyl) benzenesulfonyl fluoride (AEBSF) (SIGMA-
ALDRICH) 
BCA Protein Assay reagent Kit (PIERCE) 
Albumin from bovine serum (BSA) (SIGMA-ALDRICH) 
Markers: Seeblue Plus2, Magic Mark XP Western standard 
(INVITROGEN) 
NuPage Novex Bis-Tris Gel 12% acrylamide-bisacrylamide 
(INVITROGEN) 
Running buffer: NuPage MOPS SDS 20x (INVITROGEN) 
Antioxidant: NuPage (INVITROGEN) 
Transfer buffer: NuPage 20x (INVITROGEN) 
Chromatography paper 3MM (WHATMAN) 
Immobilon-P transfer polyvinylidene fluoride membrane (PVDF) 
(MILLIPORE) 
Tween 20 (polyoxyethylene sorbitan monolaurate) (SIGMA-
ALDRICH) 
Primary antibodies: β-Actin (SIGMA-ALDRICH), caveolin-1 (BD 
TRANSDUCTION LABORATORIES), cyclin D1, cyclin E, CDK2, CDK4, 
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pRb, Akt/pAkt, ERK/pERK, STAT3/pSTAT3, p21 (SANTA CRUZ). 
Secundary antibodies: anti-mouse IgG-HPR, anti-rabbit IgG-HPR 
(SANTA CRUZ BIOTECHNOLOGY), anti-goat IgG-HPR (PIERCE) 
Western Blotting Luminol Reagent  (SANTA CRUZ BIOTECHNOLOGY) 
Restore TM Western Blot Stripping Buffer  (THERMO SCIENTIFIC) 
High performance chemiluminescence film: Amersham 
Hyperfilm™ ECL (GE HEALTHCARE) 
Developer and replenisher (KODAK GPX) 
Fixer and replenisher (KODAK GPX) 
SiRNA duplex oligoribonucleotides (INVITROGEN) 
Oligofectamine Transfection Reagent (INVITROGEN) 
OPTI-MEM (GIBCO-INVITROGEN) 
DEPC-treated Water (INVITROGEN) 
4-hydroxytamoxifen (4-OHT) (SIGMA-ALDRICH) 
17β-estradiol (SIGMA-ALDRICH) 
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3. METHODS 
 
3.1 Cell cultures 
The human RAL (NSCLC) and SCLC-R1 cell lines were obtained 
from metastatic lesions of lung adenocarcinoma (Gasperi-Campani A 
et al, 1998a) and small cell lung carcinoma respectively (Gasperi-
Campani A et al, 1998b).  
The cells were cultured in H/H medium (a mixture containing equal 
parts of  Dulbecco’s modified Eagle’s medium and Ham’s medium) 
supplemented with 10% foetal bovine serum (FBS), 2mM L-
glutamine, 50IU/ml penicillin, 50 g/ml streptomycin and non-
essential aminoacids 1% . The human osteosarcoma cell lines MG-63 
and HOS were grown in Dulbecco’s modified Eagle’s medium 
supplemented with 10% foetal bovine serum (FBS), 2mM L-
glutamine, 50IU/ml penicillin and 50 g/ml streptomycin. 
Cultures were maintained at 37°C in a humidified atmosphere 
containing 5% CO2. The Mycoplasma Plus PCR Primer set was 
employed for mycoplasma testing. 
 
3.2 siRNA transfection 
Inhibition of Cav-1 expression in lung carcinoma and osteosarcoma 
cells was performed using small interfering RNA (siRNA). Three 
Cav-1 Stealth Select RNAi were designed to target specific sequence 
of Cav-1: 
UCGACCUGGUCAACCGCGACCCUA/UUAGGGUCGCGGUUG
ACCAGGUCGA, 
CCCACUCUUUGAAGCUGUUGGGAAA/UUUCCCAACAGCUU
CAAAGAGUGGG,  
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UCCGCAUCAACUUGCAGAAAGAAAU/AUUUCUUUCUGCAA
GUUGAUGCGGA . 
Cells were seeded in 6-well culture palates, grown to 30%-40% 
confluence and transfected with Cav-1 siRNA reconstituted in siRNA 
dilution buffer (DEPC- treated Water). Non-specific siRNA was used 
as negative control. For each plate, 4 µl of siRNA from the stock 
(40nM) was diluted into 171 µl of transfection medium (OPTI-MEM) 
and 8 µl of transfection reagent (oligofectamine reagent) was diluted 
into 17 µl of OPTI-MEM  in separate tubes. After incubating for 5 
minutes at room temperature, the diluted siRNA was mixed with 
diluted transfection reagent and further incubated at room temperature 
for 15 minute to allow complex formation. The complex was added to 
the plate containing cells with 800 µl of OPTI-MEM.  Cells were 
incubated at 37° for 4 hours. Thereafter, 1ml of culture medium 
containing 20% serum was added and cells were incubated for further 
48 or 72 hours. Cav-1 expression was assayed by immunoblot 
analysis.  
 
3.3 Growth inhibition assay 
Growth inhibition was determined using trypan blue dye exclusion 
method. Briefly, cells were seeded in 6-well culture plates at a density 
of 50.000 cells/well (MG-63, SCLC-R1 and RAL) or 15.000 
cells/well (HOS),  grown  for 24 hours and then transfected for 48 or 
72 hours. After silencing, transfection mixtures were replaced with 
fresh medium and the cells were maintained in culture for further 24h, 
48h and 72 hours.  
At each time point, cell number and viability were determined by 
trypan blue dye exclusion method.  
All data are presented as means of triplicate cultures obtained from at 
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least three independent experiments. 
 
3.4 Western blot analysis 
Cells were lysed by buffer containing: 1mM Na3VO4, 1mM 
Na4P2O7 10H2O, 10mM NaF, 1mM 4-(2-Aminoethil)-
benzenesulfonylfluoride, 1% Nonidet P-40, 10 g/ml aprotinin, 
10 g/ml leupeptin. Protein concentrations were quantified by 
bicinchoninic acid (BCA) protein assay (Smith PK et al, 1985). 
Proteins were separated by SDS-PAGE: an equal amount of protein 
samples (10 µg) was resolved on 12% SDS-polyacrylamide gel and 
then transferred onto a polyvinylidene difluoride  (PVDF) membranes. 
The membranes were blocked for 20 minutes with 5% BSA in 
phosphate-buffered saline containing 0.1% Tween 20 (PBS-T). 
Incubation with the primary antibody  was carried out at 4°C 
overnight, then the membranes were incubated with horseradish 
peroxidase-labelled secundary antibody for 1h at room temperature.
-Actin levels were determined as a loading control.  Immunological 
complexes were visualised by an ECL detection system and quantified 
by densitometric scanning. Whenever required, the blots were stripped 
by incubating the membrane at room temperature for 30 minutes in 
stripping buffer. Membranes were washed thoroughly with PBS-T and 
reprobed with required antibodies. 
 
3.5 Pharmacological treatments 
Estradiol treatments: lung cancer cells (SCLC-R1 and RAL cell 
lines) were grown in culture plates for 24 hours and then the 
treatment with 10 nM, 100 nM or 1 µM of 17β-estradiol (E2) 
was carried out in H/H phenol red-free medium supplemented 
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with 5% FBS for 5 days. E2  was prepared as a 20 µM/ml stock 
solution in absolute ethanol and stored at -20°. The drug was 
diluted freshly to the appropriate concentration in the culture 
medium before each treatment. 
4-hydroxytamoxifen treatments: lung cancer cells were grown 
in culture plates for 24 hours, followed by 24 hours in H/H 
phenol red-free medium without FBS and then the treatment 
with 1 µM, 5 µM or 10 µM of  4-hydroxytamoxifen (4-OHT) 
was carried out in H/H phenol red-free medium supplemented 
with 10% FBS for 24, 48 and 72 hours. 4-OHT was prepared as 
a 25 mM stock solution in 95% ethanol and stored at -20°. The 
drug was diluted freshly to the appropriate concentration in the 
culture medium before each treatment. 
At the end of each treatment, cell number and viability were 
determined by trypan blue dye exclusion method.  
All data are presented as means of triplicate cultures, obtained from at 
least three independent experiments. 
 
3.6 Statistical analysis 
All the results are expressed as means ± standard error (S.E.). 
Statistical analysis of the data was performed using the Student’s t-
test. P values of  0.05 were considered as significant. 
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4. RESULTS 
 
Recent data obtained in the laboratory where I performed my Doctoral 
three-year period showed a high expression of  Cav-1  in human 
cancer cell lines derived from metastatic lung cancer and from  
osteosarcoma. The cell lines were from small cell lung carcinoma 
(SCLC-R1), adenocarcinoma (RAL) and osteosarcoma (MG-63 and 
HOS) respectively. 
The starting  point  for the results presented here is the consideration 
of the complex  role exerted by Cav-1 in human malignancies, which 
seems to be dependent on histotype, stage and grade of each single 
neoplastic disease, so that it may act  as an oncosuppressor gene in 
some  tumours in vivo like ovary carcinomas, sarcomas and leukemia, 
whereas it looks like a promoter of tumour growth in thyroid, prostate, 
bladder and pancreas carcinomas, where it associates with high risk of 
metastasis, chemoresistance and apoptosis suppression. 
The aim of the prosecuting  study during my doctoral period was that 
to analyse the effects of Caveolin-1 gene silencing  on lung cancer and 
osteosarcoma cell growth and proliferation. These tumours were 
chosen due to previous results obtained in the laboratory, indicating  
the down-regulation of  Cav-1 protein as a novel target of a group of 
anticancer drugs.  
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4.1  Lung cancer 
siRNA-mediated knock-down of Cav-1  in lung cancer in vitro 
To assess the role of Cav-1 in metastatic lung cancer cell growth and 
proliferation, we knocked-down the expression of Cav-1 protein by 
small interfering RNA (siRNA) duplex  either in the RAL or in the  
SCLC-R1 metastatic cell lines. Western Blotting analysis showed a 
highly significant reduction of  protein levels in each cell line:  in 
particular, the inhibition of  Cav-1 protein expression reached  100% 
in SCLC-R1 and 80% in RAL lung cancer cell lines (fig.1). 72 hours 
after transfection, fresh medium was added to cells which were 
maintained in culture for further 72 hours. As shown in figure 2, the 
inhibition of Cav-1 expression remained  stable up to the maximum 
time of 72 hours after transfection tested.  
 
Growth inhibition of lung cancer cells by knock-down  of Cav-1 
The Cav-1 knock-down obtained either in the SCLC-R1 and in the 
RAL cell lines gave rise to the arrest of cell cycle progression in both 
cell lines,  identified immediately at the end of transfection and  
maintained stable up to the maximum time of 72 hours tested (fig.3 
and fig.4).  
 
Cav-1 silencing affects the expression of cell cycle regulatory 
proteins 
To elucidate the specific cell cycle regulatory proteins responsible for 
the growth inhibition mediated by Cav-1 knock-down, we analysed 
the expression of several molecules involved in  cell proliferation. As 
shown in figure 5, cells transfected with Cav-1 siRNA showed  a 
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marked reduction of  cyclin D1 and CDK4 expression. Consequently, 
protein levels of phospho-Rb (on ser
795
 and ser
780
) were evaluated, 
which are known to be regulated primarily by  the complex of cyclin 
D1 associated with CDK4. A  significant reduction of pRb on ser 
795
 
and ser
780
 expression was detected  either in the RAL or in the SCLC-
R1 cells treated with cav-1 siRNA (fig.5). 
 
The knock-down of Cav-1 by siRNA inhibits STAT3 signalling 
pathway 
It is known that Cyclin D1 is a target gene for  STAT3 transcription 
factor activity. For this reason, we evaluated the expression of STAT3 
and phospho-STAT3 (Tyr
705
) and results indicated a significant 
decrease of STAT3 and phospho-STAT3 (Tyr
705
) expression,  
consistent with growth inhibition due to the  Cav-1silencing (fig.6). 
As a consequence, we examined  the expression of  the kinase  
proteins Akt and ERK,  which are  known to be regulators of  STAT3 
activation. As shown in figure 6, p-Akt and p-ERK were down-
regulated in the cells treated with Cav-1 siRNA, whereas  the 
expression of total Akt and ERK remained unchanged.  
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4.2  Osteosarcoma 
 
According to the results obtained in metastatic lung cancer cell lines, 
the study proceeded with the evaluation of the effect of Cav-1 
silencing on osteosarcoma cell lines proliferation.  
siRNA-mediated knock-down  of Caveolin-1  in osteosarcoma in 
vitro 
To assess the role of Cav-1 in osteosarcoma cell growth and 
proliferation, we knocked-down the expression of Cav-1 protein by 
small interfering RNA (siRNA) duplex either in the MG-63 or in the 
HOS cell lines. Western Blotting analysis showed a highly significant 
reduction of  protein levels in each cell line: in particular, the 
inhibition of Cav-1 protein expression reached  100% in HOS and 
80% in MG-63 osteosarcoma cell lines (fig.7). 48 hours after 
transfection, fresh medium was added to cells which were maintained 
in culture for further 72 hours. As shown in figure 8, the inhibition of 
Cav-1 expression remained stable  up to the maximum time of 72 
hours after transfection tested. 
 
Growth inhibition of osteosarcoma cells by knock-down  of 
Cav1 
The Cav-1 knock-down obtained either in the  MG-63 or in the HOS 
cell lines gave rise to the arrest of cell cycle progression in the MG-63 
cell line, identified immediately at the end of transfection and 
maintained stable up to the maximum time of 72 hours tested (fig.9). 
As regards the HOS cell line,  the proliferation was reduced at the 
time of transfection and remained stable up to 24 hours, then began to 
grow and  returned near to normal levels at 72 hours after transfection 
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(fig.10). 
 
Cav-1 silencing  affects the expression of cell cycle regulatory 
proteins 
To elucidate the specific cell cycle regulatory proteins responsible for 
the growth inhibition mediated by Cav-1 knock-down, we analysed 
the expression of several molecules involved in  cell proliferation. As 
shown in figure 11, cells transfected with cav-1 siRNA showed  a  
reduction of  cyclin E and CDK2 expression more evident at 
increasing  times after transfection tested, whereas the expression of 
cyclin D1 remained unmodified.  Consequently,  protein levels of 
phospho-Rb  (on ser
795
 and ser
780
)  were evaluated, which are known 
to be regulated by the complex of cyclin E associated with CDK2.  A 
reduction of pRb on ser 
795
 expression, more evident at increasing 
times after  transfection tested,  was detected in MG-63 and HOS cells 
treated with Cav-1 siRNA (fig.11).  
 
The Cav-1 silencing induces p21-mediated negative signalling 
pathway of cell cycle 
It is known that Cyclin E-CDK2 complex may be inhibited by p21, a 
relevant negative regulator of cell cycle. For this reason we evaluated 
the expression of p21 by Western blotting analysis and the results  
showed a significant increase in p21 expression levels in each 
osteosarcoma cell line transfected with Cav-1 siRNA (fig.11).  
On the basis of these results,  we evaluated the expression of Akt, a 
protein kinase which is known to interact with caveolin-1 scaffolding 
domain and to down-regulate p21. A reduction of phospho-Akt 
expression was detected either in the MG-63 or in the HOS cells 
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treated with Cav-1 siRNA, more evident at increasing  times after 
transfection tested (fig.12). 
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4.3 Sensitivity of metastatic lung cancer to estrogen 
stimulation in vitro 
 
During my three-year period of Doctorate in Oncology I have been 
involved also in a second part of the laboratory projects, regarding the 
investigation of  the role of estrogens in lung cancer, which has not 
been yet clarified, and the functional cross-talk between Cav-1 and 
estrogens/estrogen receptors in it.  
To begin, we evaluated the effect of 17β-estradiol on the proliferation 
of  lung cancer in vitro, and to establish whether estrogens could 
modulate cell proliferation of metastatic lung cancer cells from small 
cell lung cancer  (SCLC-R1) and from lung adenocarcinoma (RAL), 
cells were exposed to increasing concentrations of  17β-estradiol (E2) 
and the effect of the treatment on cell proliferation was tested. Results 
indicate a significant increase in cellular growth in both cell lines in 
the range of concentrations used (fig.13 and fig.14). 
The second step was the evaluation of the effect, if one, of 4-hydroxy-
tamoxifen (4-OHT) on the growth of both SCLC-R1 and RAL cell 
lines. Results indicate a growth inhibitory effect exerted by 4-OHT 
either in the SCLC-R1 or in the RAL cell line (fig.15 and fig.16), in a  
dose- and time-dependent manner. 
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5. DISCUSSION 
 
Recent data obtained in the laboratory where I performed my Doctoral 
three-year period showed a high expression of  Cav-1  in human 
cancer cell lines derived from metastatic lung cancer and from  
osteosarcoma. The cell lines were from small cell lung carcinoma 
(SCLC-R1), adenocarcinoma (RAL), which have been stabilized and 
characterized in the same laboratory (Gasperi-Campani A et al, 1998a; 
Gasperi-Campani A et al, 1998b) and osteosarcoma (MG-63 and 
HOS). These last two cell lines are different as regards presence 
(HOS) or absence (MG-63) of TP53 gene. 
The starting  point  for the results presented here is the consideration 
of the complex  role exerted by Cav-1 in human malignancies, which 
seems to be dependent on histotype, stage and grade of each single 
neoplastic disease, so that it may act  as an oncosuppressor gene in 
some  tumours in vivo like ovary carcinomas, sarcomas and leukemia, 
whereas it looks like a promoter of tumour growth in thyroid, prostate, 
bladder and pancreas carcinomas in vivo, where it associates with 
high risk of metastasis, chemoresistance and apoptosis suppression. 
Lung cancer and osteosarcoma were chosen here as experimental 
models where to analyze the effects of Caveolin-1 gene silencing  on 
cell growth and proliferation due to previous results obtained in the 
laboratory, indicating  the down-regulation of Cav-1 protein as a novel 
target of a group of anticancer drugs (unpublished data).   
Emerging evidence indicates a close relation between Cav-1 protein 
and the development of lung cancer (Yoo SH et al, 2003). Recent 
studies reported  Cav-1 expression in approximately 30% of resected 
primary NSCLCs and association of it with poor prognosis of primary 
squamous cell lung cancer (Racine C et al, 1999; Razani B et al, 2000; 
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Heighway J et al, 2002; Wikman H et al, 2002). Sunaga et al, 2004,  
hypothesized  different roles for Cav-1, as a  suppressor gene in 
SCLCs and  as a growth promoter in NSCLCs, where it appears 
necessary for survival and growth.  
In the present study, we first of all analyzed the role of  Caveolin-1 in 
lung cancer cell lines, SCLC-R1 and RAL, which have a metastatic 
origin.  Our data show that Cav-1 silencing  blocks the metastatic 
proliferation either in the RAL or in the SCLC-R1 cells, suggesting a 
proliferation/survival promoting action of cav-1 in both cell lines. 
In different tumours, there is evidence suggesting that Cav-1 promotes 
cancer growth via inhibition of apoptosis through induction of cyclin 
D1 (Nagajyothi F et al, 2006), which belongs to a family of proteins 
that promote progression through  the G1-S phase of cell cycle by 
binding to cyclin-dependent kinase (CDK)-4 and as a consequence  
phosphorylating the retinoblastoma pRb protein, with release of the 
E2F transcription factor to permit  progression in the cell cycle. 
Several cancers, including breast, colon and prostate, overexpress the 
cyclin D1 gene (Jares P et al, 1997; Drobnjak M et al, 2000; Massague 
J et al,  2004; Arnold A and Papanikolaou A, 2005; Barbieri F et al, 
2004). Our results indicate both  pRb on ser
795
 and pRb on ser
780
  
down-regulation in the Cav-1 silenced RAL and SCLC-R1 metastatic 
cells, so suggesting  that the knock-down of Cav-1 may arrest cell 
proliferation by regulating pRb phosphorylation. A significant 
reduction of CDK4 and cyclin D1 expression also has been detected in 
RAL and SCLC-R1 cells treated with Cav-1 siRNA, indicating that 
the regulation of phospho-Rb induced by down-regulation of Cav-1 is 
mediated possibly via the inhibition of cyclin D1. 
Several studies (Darnell JE, 1997; Levy DE and Darnell JE, 2002; 
Benekli M et al, 2003) indicated that cyclin D1 is the primary target 
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gene of STAT3.  STATs are a family of  transcription factors, which 
may be activated by phosphorylation of a conserved tyrosine residue 
in response to extracellular signalling molecules, such as cytokines 
and growth factors (Benekli M et al, 2003; Adach A et al, 2009; 
Aktinson GP et al, 2010). There is evidence (Bromberg JF et al, 1999) 
showing that aberrant activation of STAT3 signalling plays a critical 
role in oncogenesis. STAT3  resides in fact in the cytoplasm of 
quiescent cells and may be activated  by growth factors and cytokines 
via the Janus Kinase (JAK) family of proteins. Upon activation, 
phospho-STAT3 forms homodimers or heterodimers and translocates 
to the nucleus to induce gene transcription. Constitutively active 
STAT3 and its over-expression have been detected in a wide variety 
of  human malignancies (Turkson J et al, 2000; Yu H et al, 2004) and 
aberrant active STAT3 promotes uncontrolled growth and survival 
through an up-regulation of downstream targeted genes encoding 
apoptosis inhibitors and cell-cycle regulators, such as cyclin D1 
(Grandis JR et al, 2000; Epling-Burnette PK et al, 2001; Benekli M et 
al, 2003; Diaz N et al, 2006). These abnormal changes in gene 
expression result in the inhibition of apoptosis or in the dysregulation 
of cell cycle. On the other hand, selective inactivation of STAT3 may 
lead to the inhibition of cell proliferation and to the induction of 
apoptosis in various cancer cell lines (Niu G et al, 1999; Ni Z et al, 
2000; Liu PS et al, 2010). All these findings suggest that STAT3 may 
represent a promising target for anticancer therapy. Consistent with 
growth inhibition by down-regulation of Cav-1, a significant decrease 
of STAT3 and phosphorylated STAT3 (on tyr
705
) expression levels 
was observed here in the RAL and SCLC-R1 cells where Cav-1 had 
been silenced. 
A recent study (Guruswamy S et al, 2009) demonstrated that the Cav-
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1 dependent cell survival signals are mediated through Akt activation 
as well as through its down-stream effectors, among which ERK and 
STAT3. Akt, a protein kinase associated with the scaffolding domain 
of Cav-1, is  involved in several signal transduction pathways of cell 
proliferation and apoptosis in different tumours. This protein is able to 
facilitate growth factor-mediated cell survival and to block apoptotic 
cell death. After its phosphorylation, Akt promotes the activation of 
ERK and subsequently STAT3 in different tumours (Datta SR et al, 
1999; Kortylewski M et al, 2003).  A significant reduction of pAkt 
expression was observed here in the RAL and SCLC-R1 cells where 
Cav-1 had been silenced, together with a  significant decrease in the 
phosphorylation of ERK. The ERK signalling cascade is critical for 
transducting signals essential for cell survival and activated ERK can 
phosphorylate a variety of transcription factors regulating expression 
genes such as STAT3.  
In summary, the results obtained here in metastatic lung cancer in 
vitro indicate the activation of Akt by its interaction with the 
scaffolding domain of  Cav-1, and this promotes the ERK and STAT3 
phosphorylation and subsequently the transcription of cyclin D1 gene. 
The activation of cyclin D1 expression and its interaction with CDK4 
lead to pRb phosphorylation and then to progression through the cell 
cycle. This is the first report of a block of metastatic lung cancer 
proliferation obtained by the Cav-1 silencing, in the same time 
suggesting  a new cell cycle inhibiting pathway, mediated by Cav-1 
knock-down, in lung cancer and providing  new insights into the 
molecular mechanisms underlying the pro-survival and tumour-
promoting functions of Cav-1.  
As regards osteosarcoma, it is known that Cav-1 frequently acts  as an 
oncosuppressor in sarcomas in vivo (Wiechen K et al, 2001; Williams 
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TM et al, 2004; Sloan EK et al, 2004). However, its role in bone 
development and maturation as well as in osteoblast transformation 
and sarcoma progression is still undefined. Recently Cav-1 has been 
found  necessary for tumorigenesis of  Ewing’s sarcoma (Tirado OM 
et al, 2006).  
Here we  demonstrate that the suppression of Cav-1 obtained in the 
osteosarcoma MG-63 and HOS cell lines by siRNA  results in the 
block of MG-63 growth and in the slowing down of HOS growth, 
suggesting a proliferation/survival-promoting action of Cav-1, 
different in the cell lines analysed. We are now studying in the lab the 
possible involvement of TP53 in this result. 
It is known that cyclins, in particular cyclin D1 and cyclin E, by 
binding to cyclin-dependent kinases (CDKs), regulate the cell cycle 
promoting progression through the G1-S phase in osteosarcoma also 
(Nurse PM, 2002; Sherr CJ and Roberts JM, 2004). In our hands, in 
the MG-63 and HOS cells treated with Cav-1 siRNA,  the cyclin E 
expression was  significantly decreased, whereas  cyclin D1 
expression remained unmodified, indicating that the inhibition of 
proliferation by Cav-1 knock-down is mediated here possibly via the 
inhibition of cyclin E.  
It is known that the cyclin E-CDK2 complex regulates pRb 
phosphorylation in osteosarcoma also, which represents  a critical step 
in the G1 to S phase transition (Nevins JR et al, 1997).  The results 
presented here indicate that both CDK2 and pRb (on ser
795
) are down-
regulated in transfected MG-63 and HOS cells, so suggesting  that the 
knock-down of Cav-1 affects cell proliferation by regulating pRb 
phosphorylation.  
Two different cyclin-dependent kinase inhibitors (CDKI) are known: 
the INK4 family and the CIP/KIP family which are able to stop the 
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cell cycle progression in response to appropriate regulatory signals. 
The first group is composed by four members, p15, p16, p18 and p19, 
which inhibit the kinase activity of the CDK4/cyclinD1 complexes; 
the CYP/KIP family is composed by three members, p21, p27 and 
p57, that hinder the kinase activity of CDK2/cyclinE complexes. 
Consistent with growth inhibition or slowing down by down-
regulation of Cav-1, a significant increase of p21 expression  has been 
observed in MG-63 and HOS cells where Cav-1 had been silenced. As 
already stated above,  it  has been demonstrated that Akt down-
regulates p21 expression (Viglietto G et al, 2002; Andreu EJ et al, 
2005; Motti ML et al, 2005) and that Akt is a tyrosine kinase which 
interacts with Cav-1 scaffolding domain  and plays a relevant role in 
tumorigenesis, affecting the growth and survival of cancer cells 
through the phosphorylation and relocalization of key regulatory 
molecules such as p21 (Zhou BP et al, 2001). In the present study, a 
significant reduction of  phospho-Akt expression has been detected in 
Cav-1 knocked-down MG-63 and HOS cells. 
In summary,  we show in the present study that the activation of Akt, 
by its interaction with the scaffolding domain of  Cav-1, promotes the 
down-regulation of p21 and thus the activation of cyclin E-CDK2 
complex which lead to Rb phosphorylation and to progression through 
cell cycle. We show also that the suppression of Cav-1 expression 
obtained by siRNA, inhibiting this signalling cascade, affects the MG-
63 and HOS osteosarcoma cell lines growth, causing the arrest of cell 
proliferation in MG-63 cells and a slowing down of it in the HOS 
cells. The study is in progress to understand the role that TP53 may 
have in this respect. 
As for the results obtained in metastatic lung cancer cells, those 
obtained in osteosarcoma cells suggest a new cell cycle inhibitor 
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pathway, Cav-1 knock-down mediated, and provide new insights into 
the molecular mechanisms underlying the pro-survival and tumour-
promoting role of Cav-1 in osteosarcoma.  
 
As for the second part of the laboratory projects, in which I have been 
involved, this regards the investigation on the role of estrogens in lung 
cancer, which has not jet been clarified,  and the functional cross-talk 
between Cav-1 and estrogens/ estrogen receptors in it.  
It has been recently reported in the literature the 2-fold higher 
frequency of lung cancer in never-smoking women than in never-
smoking men,  suggesting  the involvement of gender-dependent 
factors, like estrogens, in the etiology of this tumour (Omoto Y et al, 
2001.) 
However, the role of estrogens in lung cancer is unclear: several 
studies on sex differences in lung cancer risk and disease presentation 
have suggested that estrogen-signalling pathways may play a key role 
in the genesis and in controlling the growth of lung cancer (Stabile LP 
and Siegfried JM, 2003);  on the other hand, the higher survival rates 
for women with non-small cell lung cancer (NSCLC) in respect to 
men seems to indicate a protective effect of estrogens (Moore KA et 
al, 2003.) 
The cellular response to estrogens is mediated by estrogen receptor α 
(ERα) and  β (ERβ) and the orphan receptor GPR30 (G protein-
coupled receptor-30), which has been recently implicated in rapid and 
specific estrogens binding in mediating the action of several 
estrogenic compounds (Madeo A et al, 2010). 
Dougherty SM et al, in nine different human adenocarcinoma cell 
lines from male or female lung cancer patients, demonstrated that 
although no differences in the levels of ERα and ERβ could be 
41 
 
detected, there are significant differences in cellular responses to 17β-
estradiol (E2) and to the anti-estrogens 4-hydroxytamoxifen (4-OHT) 
between cell lines from males and females. In his study,  whereas the 
proliferation of the cell lines from females is stimulated by E2 and 
blocked by concomitant administration of 4-OHT, the cell lines from 
males do not respond to these treatments (Dougherty SM et al, 2006).   
In the present study, we evaluated the effect of 17β-estradiol (E2) on 
the proliferation of  lung cancer in vitro, to establish whether 
oestrogens could modulate cell proliferation of metastatic lung cancer 
cells from small cell lung cancer (SCLC-R1) and from lung 
adenocarcinoma (RAL) in a manner dependent or not by the original 
gender of the patients from which the cells had been derived. The cell 
lines express ERβ and GPR30 and not ERα (previous data from this 
laboratory). We could observe a significant increase in cellular growth 
in both cell lines in the range of E2 concentrations used, 
independently of the different male (SCLC-R1) or female (RAL) 
origin.  
On the bases of these results, we proceeded investigating the growth 
inhibitory effect, if one, exerted by 4-OHT either in the SCLC-R1 or 
in the RAL  cell lines and could observe that both cell lines are 
sensitive to 4-OHT antiproliferative effect;  additional studies are now 
in progress in the lab  to a better understanding of  the ERs (ERα, 
ERβ, GPR30) role in these tumours.  
 
 
F. Pancotti, L. Roncuzzi, M. Maggiolini, A. Gasperi-Campani 
Caveolin-1 silencing blocks metastatic lung cancer proliferation in 
vitro (2010 nov, submitted) 
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6. FIGURES 
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Figure 1.  siRNA-mediated down-regulation of Cav-1 expression 
in lung cancer SCLC-R1 and RAL cell lines: cells were transfected 
with siRNA targeted against Cav-1 (siRNA) or a random sequence (C) 
for 72 hours and the protein expressions were examined by Western 
blot analysis. β-Actin was used as a protein loading control. The 
results are representative of 3 independent experiments.   
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Figure 2.  siRNA-mediated down-regulation of Cav-1 expression 
in lung cancer SCLC-R1 and RAL cell lines: cells were transfected 
with siRNA targeted against cav-1 (+) or a random sequence (-). 72 
hours after transfection (T0) and after 24, 48 and 72 hours, the protein 
expressions were examined by Western blot analysis . β-Actin was 
used as a protein loading control. The results are representative of 3 
independent experiments.   
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Figure 3. Effect of siRNA-mediated down-regulation of Cav-1 on 
the proliferation of human lung cancer SCLC-R1 cell line: 72 
hours after transfection (0-T0), cells were cultured for 24, 48 and 72 
hours, the cell proliferation was analyzed and subsequently the growth 
curves were plotted. The results are representative of 3 independent 
experiments. 
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Figure 4. Effect of siRNA-mediated down-regulation of Cav-1 on 
the proliferation of human lung cancer RAL cell line: 72 hours 
after transfection (0-T0), cells were cultured for 24, 48 and 72 hours, 
the cell proliferation was analyzed and subsequently the growth 
curves were plotted. The results are representative of 3 independent 
experiments. 
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Figure 5. Cav-1 inhibition affects the expression of cell cycle 
regulatory proteins: SCLC-R1 and RAL cells were treated with Cav-
1 siRNA (+) or control siRNA (-) for 72 hours. Immediately after 
transfection (T0) and after 24, 48 and 72 hours, cyclin D1, CDK4, 
pRb(ser
795
) and pRb(ser
780
) protein expressions were examined by 
Western blot analysis. β-Actin was used as a protein loading control. 
The results are representative of 3 independent experiments.   
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Figure 6. Effect of down-regulation of Cav-1 on STAT3 signalling 
pathway: SCLC-R1 and RAL cells were treated with Cav-1 siRNA 
(+) or control siRNA (-) for 72 hours. Immediately after transfection 
(T0) and after 24, 48 and 72 hours, STAT3, p-STAT3, ERK, p-ERK, 
Akt and p-Akt protein expressions were examined by Western blot 
analysis. β-Actin was used as a protein loading control. The results are 
representative of 3 independent experiments. 
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Figure 7.  siRNA-mediated down-regulation of Cav-1 expression 
in human osteosarcoma MG-63 and HOS cell lines: cells were 
transfected with siRNA targeted against Cav-1 (siRNA) or a random 
sequence (C) for 48 hours and the protein levels were examined by 
Western blot analysis. β-Actin was used as a protein loading control. 
The results are representative of 3 independent experiments.   
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Figure 8. siRNA-mediated down-regulation of Cav-1 expression in 
human osteosarcoma MG-63 and HOS cell lines: cells were 
transfected with siRNA targeted against Cav-1 (Cav-1 siRNA) or a 
random sequence (C). 48 hours after transfection (T0) and after 24, 48 
and 72 hours, the protein expressions were examined by Western blot 
analysis. β-Actin was used as a protein loading control. The results are 
representative of 3 independent experiments.   
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Figure 9. Effect of siRNA-mediated down-regulation of Cav-1 on 
the proliferation of human osteosarcoma MG-63 cell line: 48 hours 
after transfection (0-T0), cells were cultured for 24, 48 and 72 hours, 
the cell proliferation was analyzed and subsequently the growth 
curves were plotted. The results are representative of 3 independent 
experiments. 
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Figure 10. Effect of siRNA-mediated down-regulation of Cav-1 on 
the proliferation of human osteosarcoma HOS cell line: 48 hours 
after transfection (0-T0), cells were cultured for 24, 48 and 72 hours, 
the cell proliferation was analyzed and subsequently the growth 
curves were plotted. The results are representative of 3 independent 
experiments. 
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Figure 11. Cav-1 inhibition affects the expression of cell cycle 
regulatory proteins: MG-63 and HOS cells were treated with Cav-1 
siRNA or control siRNA (C) for 48 hours. Immediately after 
transfection (T0) and after 24, 48 and 72 hours, phospho-Rb (on 
ser
795
), cyclin E, CDK2 and p21 protein expressions were examined 
by Western blot analysis using the respective antibodies. β-Actin was 
used as a protein loading control. The results are representative of 3 
independent experiments.   
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Figure 12. Effect of down-regulation of Cav-1 on p21 signalling 
pathway: MG-63 and HOS cells were treated with Cav-1 siRNA or 
control siRNA (C) for 48 hours. Immediately after transfection (T0) 
and after 24, 48 and 72 hours, Akt /p-Akt protein expressions were 
examined by Western blot analysis. β-Actin was used as a protein 
loading control. The results are representative of 3 independent 
experiments. 
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Figure 13.  Effect of 17β-estradiol on the proliferation of RAL 
lung cancer cells: RAL cells were treated with 17β-estradiol. 5 days 
after treatment, the cell proliferation was analyzed and subsequently 
the histograms were plotted (C: untreated cells).   
The results are representative of 3 independent experiments. 
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Figure 14.  Effect of 17β-estradiol on the proliferation of SCLC-
R1 lung cancer cells: SCLC-R1 cells were treated with 17β-estradiol. 
5 days after treatment, the cell proliferation was analyzed and 
subsequently the histograms were plotted (C: untreated cells).  
The results are representative of 3 independent experiments.   
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Figure 15. Effect of  4-OHT on the  proliferation of  RAL lung 
cancer cells: RAL cells were treated with 4-OHT. 24, 48 and 72 hours 
after treatment, the cell survival was analyzed and subsequently the 
growth curves were plotted. The results are representative of 3 
independent experiments. 
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Figure 16. Effect of  4-OHT on the  proliferation of SCLC-R1 lung 
cancer cells: SCLC-R1 cells were treated with 4-OHT. 24, 48 and 72 
hours after treatment, the cell survival was analyzed and subsequently 
the growth curves were plotted. The results are representative of 3 
independent experiments. 
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